洛匹那韦/利托那韦联合α-干扰素治疗新型冠状病毒肺炎的临床疗效  

Clinical efficacy of Lopinavir-Ritonavir combined with interferon alpha in COVID-19

作　　者：王妍妮 索涛[1] 范慧[1] 赵考昌 邹进晶[1] 伍丹丹[1] 汤贵良 陈国忠[1] WANG Yanni;SUO Tao;FAN Hui;ZHAO Kaochang;ZOU Jinjing;WU Dandan;TANG Guiliang;CHEN Guozhong(Dept,of Respiratory and Critical Care Medicine,Renmin Hospital of Wuhan U niversity,Wuhan 430060,Hubei,China)

机构地区：[1]武汉大学人民医院呼吸与危重症医学科,湖北武汉430060

出　　处：《武汉大学学报（医学版）》2021年第4期594-598,共5页Medical Journal of Wuhan University

基　　金：湖北省科技厅新型肺炎应急科技攻关项目(编号:2020FCA017);中央高校基本科研业务费专项资金资助(编号:2042020KFXG15)。

摘　　要：目的:评价洛匹那韦/利托那韦联合α-干扰素治疗新型冠状病毒肺炎(COVID-19)的临床疗效。方法:纳入2020年1月25日—2月12日武汉大学人民医院收治的COVID-19患者109例,58例为α-干扰素组(A组),51例为洛匹那韦/利托那韦联合α-干扰素组(B组)。比较两组间治疗效果,组间比较采用Kruskal-Wallis检验或卡方检验。结果:两组患者基线资料基本一致。治疗7 d时B组的肺部炎症改善率较A组明显增高,B组患者白细胞计数和中性粒细胞计数在正常值范围内较基线值均上升;治疗14 d时B组白细胞计数、淋巴细胞计数、CD4细胞计数及CD8细胞计数较基线值上升,C反应蛋白较基线值下降,差异均具有统计学意义。结论:洛匹那韦/利托那韦联合α-干扰素治疗新型冠状病毒肺炎可以加快患者肺部炎症吸收,增高患者体内免疫细胞水平。Objective:To evaluate the clinical efficacy of Lopinavir-Ritonavir combined with interferon alpha on coronavirus disease 2019(COVID-19).Methods:A prospective and real-world observational clinical research was conducted on COVID-19 cases who were admitted to the Renmin Hospital of Wuhan University from January 25, 2020 to February 12, 2020.Of the 109 cases involved, 58 cases were treated with interferon alpha(group A), while 58 cases were treated with Lopinavir-Ritonavir combined with interferon alpha(group B).The recent outcomes were compared between the two groups by Kruskal Wallis test or Chi square test.Results:The baseline data of the two groups were basically the same.On the 7 th day after treatment, the lung inflammation in group B was higher than in group A, and the leukocyte count and neutrophil count in the normal range increased as compared with the baseline value in group B.On the 14 th day after treatment, the leukocyte count, lymphocyte count, CD4/CD8 cell count increased as compared with the baseline value, while CRP decreased from baseline in the B group, with statistically significant differnce.Conclusion:Lopinavir-Ritonavir combined with interferon alpha can accelerate the improvement of pulmonary inflammation, and increase the levels of immune cells in COVID-19 patients.

关 键 词：洛匹那韦/利托那韦 Α-干扰素 新型冠状病毒肺炎 临床疗效 

分 类 号：R978.7[医药卫生—药品]